Evidence map›Paper›PMID 31221200›Full record

ArticleCritical care (London, England)2019

Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.

Louis M Guzzi, Tobias Bergler, Brian Binnall, Daniel T Engelman, Lui Forni, Michael J Germain, Eric Gluck, Ivan Göcze, Michael Joannidis, Jay L Koyner and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Changes in Novel AKI Biomarkers after Exercise. A Systematic Review.International journal of molecular sciences · 2020
    Pooled it
  5. Guideline
  6. Trial
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Kidney Injury Following Cardiac Surgery: A Review of Our Current Understanding.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Louis M GuzziFlorida Hospital, 601 E. Rollins Street, Orlando, FL, 32803, USA.
Tobias BerglerUniversity Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Brian BinnallBaystate Medical Center, 759 Chestnut Street, Springfield, MA, 01107, USA.
Daniel T EngelmanBaystate Medical Center, 759 Chestnut Street, Springfield, MA, 01107, USA.
Lui ForniThe Royal Surrey County Hospital NHS Foundation Trust, Egerton Rd, Guildford, Surrey, GU2 7XX, UK.
Michael J GermainBaystate Medical Center, 759 Chestnut Street, Springfield, MA, 01107, USA.
Eric GluckSwedish Covenant Hospital, 5145 N California Ave, Chicago, IL, 60625, USA.
Ivan GöczeUniversity Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Michael JoannidisDivision of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Jay L KoynerSection of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Ave, Suite S-507, MC5100, Chicago, IL, 60637, USA.
V Seenu ReddyTristar Centennial Medical Center, 2400 Patterson St #307, Nashville, TN, 37203, USA.
Thomas RimmeléHospices Civils de Lyon, Edouard Herriot Hospital, 5 Place d'Arsonval, 69003, Lyon, France.
Claudio RoncoDepartment of Nephrology University of Padua, Padua Italy; San Bortolo Hospital, Vicenza, Italy; International Renal Research Institute Vicenza, Vicenza, Italy.
Julien TextorisHospices Civils de Lyon, Edouard Herriot Hospital, 5 Place d'Arsonval, 69003, Lyon, France.
Alexander ZarbockUniversity Hospital Münster, Albert-Schweitzer Campus 1, Building A1, 48149, Münster, Germany.
John A KellumThe Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, 3347 Forbes Avenue, Suite 220, Pittsburgh, PA, 15213, USA. kellumja@upmc.edu.ORCID 0000-0003-1995-2653

Funding

Astute Medical nabioMérieux na
6 · The paper itself

Abstract

backgroundThe first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically.

methodsWe invited a group of experts knowledgeable on the utility of this test for kidney injury to a panel discussion regarding the appropriate use of the test. Specifically, we wanted to identify which patients would be appropriate for testing, how the results are interpreted, and what actions would be taken based on the results of the test. We used a modified Delphi method to prioritize specific populations for testing and actions based on biomarker test results. No attempt was made to evaluate the evidence in support of various actions however.

resultsOur results indicate that clinical experts have developed similar practice patterns for use of the [TIMP-2]•[IGFBP7] test in Europe and North America. Patients undergoing major surgery (both cardiac and non-cardiac), those who were hemodynamically unstable, or those with sepsis appear to be priority patient populations for testing kidney stress. It was agreed that, in patients who tested positive, management of potentially nephrotoxic drugs and fluids would be a priority. Patients who tested negative may be candidates for "fast-track" protocols.

conclusionIn the experience of our expert panel, biomarker testing has been a priority after major surgery, hemodynamic instability, or sepsis. Our panel members reported that a positive test prompts management of nephrotoxic drugs as well as fluids, while patients with negative results are considered to be excellent candidates for "fast-track" protocols.

Indexed as

Acute Kidney InjuryBiomarkersHumansInsulin-Like Growth Factor Binding ProteinsTissue Inhibitor of Metalloproteinase-2Biomarkersinsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsTissue Inhibitor of Metalloproteinase-2Acute kidney injuryBiomarker technologyBiomarker testingClinical guidelinesCritical careDiagnosisExpert panelInsulin-like growth factor binding protein 7ProtocolsTissue inhibitor of metalloproteinases-2

Identifiers

PMID31221200
PMCPMC6585126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.